Dylan Dupuis, Ph.D., has joined ROTH MKM’s healthcare research team as managing director, senior research analyst covering biotechnology.
His research coverage is expected to include micro-cap and small-cap biotechnology companies across the therapeutic space, with an initial focus on companies developing novel drugs for immunology, inflammatory diseases, metabolic diseases, and oncology.
Prior to joining ROTH MKM, Dr. Dupuis was a SMID-cap biotech analyst at Altium Capital, a healthcare-focused hedge fund. Prior to Altium, he spent two years at SVB Leerink as VP – equity research, senior associate. Prior to SVB Leerink, he was a research associate at B. Riley FBR.
In a statement, Jeff Martin, co-director of research at ROTH, said Dr. Dupuis’ strong academic background combined with his experience covering innovative and underappreciated biotechnology companies will undoubtedly serve our clients well.